EMEA-001776-PIP02-17-M01

Table of contents

Key facts

Invented name
Skyrizi
Active substance
Risankizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0039/2021
PIP number
EMEA-001776-PIP02-17-M01
Pharmaceutical form(s)
  • Solution for injection
  • Age-appropriate pharmaceutical form
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
AbbVie Ltd

E-mail: paediatricteam@abbvie.com
Tel. +44 (0)1628 408248

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating